<DOC>
	<DOCNO>NCT00538317</DOCNO>
	<brief_summary>In patient acute myocardial infarction manage prehospital setting , treat primary angioplasty , evaluate benefit early administration tirofiban , powerful GPIIbIIIa inhibitor . Patients randomise early administration ambulance administration cathlab . The primary endpoint TIMI 2-3 flow first coronary opacification culprit artery .</brief_summary>
	<brief_title>GPIIbIIIa Inhibitors RESCUe RESURCOR Networks Acute Myocardial Infarction</brief_title>
	<detailed_description />
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<criteria>Age &gt; 18 year Information give patient consent obtain Thoracic pain symptom infarction Symptoms &lt; 12 hour ST deviation identify electrocardiography ( ECG ) least 2 contiguous lead Transfer time angioplasty room evaluate coordinate doctor le 90 minute ( ECG diagnosis arrival angioplasty room ) Exclusion criterion Physiological pathological condition compatible revascularisation procedure ( acute phase myocardial infarction ( MI ) Administration fibrinolytics another antiGPIIBIIIa previous seven day Contraindications aspirin tirofiban heparin Diagnosed severe kidney failure ( dialysis , creatinin &gt; 350Âµmol/l Pregnancy Time transfer angioplasty room evaluate coordinate doctor 90 minute Subject participate another trial Subject high hemorrhagic risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2008</verification_date>
	<keyword>Acute myocardial infarction ,</keyword>
	<keyword>GPIIbIIIa inhibitor ,</keyword>
	<keyword>primary angioplasty ,</keyword>
	<keyword>tirofiban</keyword>
</DOC>